Pathophysiological mechanisms for the respiratory syncytial virus-reactive airway disease link

Respiratory Research

Volumn 3, Issue SUPPL.1, 2002, Pages

  Piedimonte, Giovanni ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

asthma; palivizumab; pediatrics; prevention; reactive airway disease; respiratory syncytial virus

Indexed keywords

EID: 4243781602     PISSN: 14659921     EISSN: 1465993X     Source Type: Journal    
DOI: 10.1186/rr185     Document Type: Article

References (20)

1. Centers for Disease Control and Prevention Respiratory syncytial virus activity: United States, 1999-2000 season. MMWR Morb Mortal Wkly Rep 2000, 49:1091-1093. Centers for Disease Control and Prevention.
2. Sims DG, Downham MA, Gardner PS, Webb JKG, Weightman D. Study of 8-year-old children with a history of respiratory syncytial virus bronchiolitis in infancy. BMJ 1978, 1:11-14. 1602461, 620129, 10.1136/bmj.1.6104.11.
3. Pullan CR, Hey EN. Wheezing, asthma, and pulmonary dysfunction 10 years after infection with respiratory syncytial virus in infancy. BMJ 1982, 284:1665-1669. 1498624, 6805648, 10.1136/bmj.284.6330.1665.
4. McConnochie KM, Roghmann KJ. Bronchiolitis as a possible cause of wheezing in childhood: new evidence. Pediatrics 1984, 74:1-10.
5. Mok JY, Simpson H. Outcome for acute bronchitis, bronchiolitis, and pneumonia in infancy. Arch Dis Child 1984, 59:306-309. 1628672, 6721555, 10.1136/adc.59.4.306.
6. Carlsen KH, Larsen S, Bjerve O, Laegaard J. Acute bronchiolitic pre-disposing factors and characterization of infants at risk. Pediatr Pulmonol 1987, 3:153-160. 10.1002/ppul.1950030308, 3615038.
7. Murray M, Webb MS, O'Callaghan, Swarbrick AS, Milner AD. Respiratory status and allergy after bronchiolitis. Arch Dis Child 1992, 67:482-487. 1793348, 1580676, 10.1136/adc.67.4.482.
8. Osundwa VM, Dawod ST, Ehlayel M. Recurrent wheezing in children with respiratory syncytial virus (RSV) bronchiolitis. Arch Dis Child 1993, 152:1001-1003.
9. Noble V, Murray M, Webb MS, Alexander J, Swarbrick AS, Milner AD. Respiratory status and allergy nine to 10 years after acute bronchiolitis. Arch Dis Child 1997, 76:315-319. 1717138, 9166022, 10.1136/adc.76.4.315.
10. Glezen WP, Taber LH, Frank AL, Kasel JA. Risk of primary infection and reinfection with respiratory syncytial virus. Am J Dis Child 1986, 140:543-546.
11. Sigurs N, Bjarnason R, Sigurbergsson F, Kjellman B. Respiratory syncytial virus bronchiolitis in infancy is an important risk factor for asthma and allergy at age 7. Am J Respir Crit Care Med 2000, 161:1501-1507.
12. Stein RT, Sherrill D, Morgan WJ, Holber CJ, Holonen M, Taussig LM, Wright AL, Martinez FD. Respiratory syncytial virus in early life and risk of wheeze and allergy by age 13 years. Lancet 1999, 354:541-545. 10.1016/S0140-6736(98)10321-5, 10470697.
13. Piedimonte G, Rodriguez MM, King KA, Mclean S, Jiang X. Respiratory syncytial virus upregulates expression of the substance P receptor in rat lungs. Am J Physiol 1999, 277:L831-L840.
14. King KA, Hu C, Rodriguez MM, Romaguera R, Jiang X, Piedimonte G. Exaggerated neurogenic inflammation and substance P receptor upregulation in RSV-infected weanling rats. Am J Respir Cell Mol Biol 2001, 24:101-107.
15. Wedde-Beer K, Hu C, Rodriguez MM, Piedimonte G. Leukotrienes mediate neurogenic inflammation in lungs of young rats infected with respiratory syncytial virus. Am J Physiol Lung Cell Mol Physiol 2002, 282:L1143-L1150.
16. Hu C, Wedde-Beer K, Auais A, Rodriguez MM, Piedimonte G. Nerve growth factor (NGF) and NGF receptors in respiratory syncytial virus (RSV)-infected lungs. Am J Physiol Lung Cell Mol Physiol 2002, 10.1152/ajplung.00414.2001.
17. Simoes EAF. Treatment and prevention of respiratory syncytial virus lower respiratory tract infection. Long-term effects on respiratory outcomes. Am J Respir Crit Care Med 2001, 163:S14-S17.
18. The IMpact-RSV Study group Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 1998, 102:531-537. The IMpact-RSV Study group.
19. Piedimonte G, King KA, Holmgren NL, Bertrand PJ, Rodriguez MM, Hirsch RL. A humanized monoclonal antibody against respiratory syncytial virus (palivizumab) inhibits RSV-induced neurogenic-mediated inflammation in rat airways. Pediatr Res 2000, 47:351-356. 10.1203/00006450-200003000-00011, 10709734.
20. Wenzel SE, Gibbs R, Lehr MV, Simoes EAF. Respiratory outcomes in high-risk children 7-10 years after prophylaxis with respiratory syncytial virus immune globulin. Am J Med 2002, 112:627-633. 10.1016/S0002-9343(02)01095-1, 12034412.